| JNJ |
Johnson & Johnson |
72%
|
days (1) For the year ended December 31, 2024. The design and performance of OncoScreen ™ Plus and OncoCompass ™ Plus has been endorsed by their adoption in over 20 clinical trials and studies. For e… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from BNR graph: days (1) For the year ended December 31, 2024. The design and performance of OncoScreen ™ Plus and OncoCompass ™ Plus h… |
| MS-PE |
Morgan Stanley |
72%
|
Reciprocal relationship from MS-PE graph: Reciprocal relationship from BNR graph: e information contained in any notice of a shareholders’ meeting received by the depositary from us. I. Subsidiary In… |
| MS-PK |
Morgan Stanley |
72%
|
e information contained in any notice of a shareholders’ meeting received by the depositary from us. I. Subsidiary Information Not applicable. 147 Table of Contents J. Annual Report to Security Holde… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
days (1) For the year ended December 31, 2024. The design and performance of OncoScreen ™ Plus and OncoCompass ™ Plus has been endorsed by their adoption in over 20 clinical trials and studies. For e… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from BNR graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from BNR graph: Reciprocal relationship from MYGN gra… |
| BEIJING-BIOTECHNOLOGY-CO-LTD |
BEIJING-BIOTECHNOLOGY-CO-LTD |
62%
|
idated Total Non-VIE entities RMB RMB RMB RMB US$ (in thousands) Net cash generated from (used in) operating activities 68,290 (160,551 ) — (92,261 ) (12,640 ) Net cash used in investing activities (… |
| BEIJING-BURNING-ROCK-BIOTECH-LIMITED |
BEIJING-BURNING-ROCK-BIOTECH-LIMITED |
62%
|
mments) which expanded the scope of application of cybersecurity review, established the data classified and categorized protection system, and defined the relevant rules for cross-border security ma… |
| BIOTEK-INSTRUMENTS-INC |
BIOTEK-INSTRUMENTS-INC |
62%
|
iv) a decrease in amortized expenses for office building. Selling and marketing expenses Our selling and marketing expenses decreased by 22.9% to RMB190.9 million for 2024 from RMB247.7 million for 2… |
| BR-HONG-KONG-LIMITED |
BR-HONG-KONG-LIMITED |
62%
|
mments) which expanded the scope of application of cybersecurity review, established the data classified and categorized protection system, and defined the relevant rules for cross-border security ma… |
| CO-LLC-BOFA-SECURITIES-INC |
CO-LLC-BOFA-SECURITIES-INC |
62%
|
e information contained in any notice of a shareholders’ meeting received by the depositary from us. I. Subsidiary Information Not applicable. 147 Table of Contents J. Annual Report to Security Holde… |
| COMPANY-LLC |
COMPANY-LLC |
62%
|
e information contained in any notice of a shareholders’ meeting received by the depositary from us. I. Subsidiary Information Not applicable. 147 Table of Contents J. Annual Report to Security Holde… |
| DIZAL-PHARMACEUTICAL-CO-LTD |
DIZAL-PHARMACEUTICAL-CO-LTD |
62%
|
. This graph demonstrates that even for the most signal-scarce sample—0.00001 (0.001%) tumor cell DNA shown as the yellow bar in the graph—the overall sample can still be recognized as positive, as i… |
| EARLY-CANCER-DETECTION-TECHNOLOGIES |
EARLY-CANCER-DETECTION-TECHNOLOGIES |
62%
|
-based cancer therapy selection tests, hospitals face multiple challenges in adopting these tests, which have technically sophisticated workflows. In 2016, we became China’s first NGS-based cancer th… |
| GENE-COMPANY-LIMITED |
GENE-COMPANY-LIMITED |
62%
|
iv) a decrease in amortized expenses for office building. Selling and marketing expenses Our selling and marketing expenses decreased by 22.9% to RMB190.9 million for 2024 from RMB247.7 million for 2… |
| GUANGDONG-HEALTH-DEPARTMENT-GUANGZHOU-BURNING-RO |
GUANGDONG-HEALTH-DEPARTMENT-GUANGZHOU-BURNING-RO |
62%
|
ent are not fully consistent with TCFD recommendations and that further work is required to enhance the identification, impact and reporting for climate-related risks and opportunities. As of the dat… |
| GUANGZHOU-BURNING-ROCK-BIOTECH-LIMITED |
GUANGZHOU-BURNING-ROCK-BIOTECH-LIMITED |
62%
|
mments) which expanded the scope of application of cybersecurity review, established the data classified and categorized protection system, and defined the relevant rules for cross-border security ma… |
| GUANGZHOU-BURNING-ROCK-DX-CO-LTD |
GUANGZHOU-BURNING-ROCK-DX-CO-LTD |
62%
|
. Total share-based compensation expenses recognized for the years ended December 31, 2023, 2024 and 2025 were as follows: For the years ended December 31, 2023 2024 2025 RMB RMB RMB US$ Cost of reve… |
| GUANGZHOU-BURNING-ROCK-MEDICAL-EQUIPMENT-CO-LTD |
GUANGZHOU-BURNING-ROCK-MEDICAL-EQUIPMENT-CO-LTD |
62%
|
ent are not fully consistent with TCFD recommendations and that further work is required to enhance the identification, impact and reporting for climate-related risks and opportunities. As of the dat… |
| HONG-KONG-BR-HONG-KONG-LIMITED |
HONG-KONG-BR-HONG-KONG-LIMITED |
62%
|
ur ability to engage in certain kinds of business operations; they may also limit our ability to raise capital from U.S. and other sources if we engage in the development of technologies specified in… |
| LAKE-BLEU-PRIME-HEALTHCARE-MASTER-FUND-LIMITED |
LAKE-BLEU-PRIME-HEALTHCARE-MASTER-FUND-LIMITED |
62%
|
iv) a decrease in amortized expenses for office building. Selling and marketing expenses Our selling and marketing expenses decreased by 22.9% to RMB190.9 million for 2024 from RMB247.7 million for 2… |
| LEADING-GROUP |
LEADING-GROUP |
62%
|
ent are not fully consistent with TCFD recommendations and that further work is required to enhance the identification, impact and reporting for climate-related risks and opportunities. As of the dat… |
| LIQUID-BIOPSY-TECHNOLOGIES |
LIQUID-BIOPSY-TECHNOLOGIES |
62%
|
-based cancer therapy selection tests, hospitals face multiple challenges in adopting these tests, which have technically sophisticated workflows. In 2016, we became China’s first NGS-based cancer th… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
ur ability to engage in certain kinds of business operations; they may also limit our ability to raise capital from U.S. and other sources if we engage in the development of technologies specified in… |
| SHANGHAI-CO-LTD |
SHANGHAI-CO-LTD |
62%
|
993 22,878 29.7 578 83 0.1 155,540 22,242 28.8 316,111 45,203 58.6 Revenues from sales of products — — 223,457 31,954 41.4 — — — 223,457 31,954 41.4 159,993 22,878 29.7 224,035 32,037 41.5 155,540 22… |
| ZTE-CORPORATION |
ZTE-CORPORATION |
62%
|
iv) a decrease in amortized expenses for office building. Selling and marketing expenses Our selling and marketing expenses decreased by 22.9% to RMB190.9 million for 2024 from RMB247.7 million for 2… |
| ZTEK |
Zentek Ltd. |
62%
|
Reciprocal relationship from ZTEK graph: Reciprocal relationship from BNR graph: Reciprocal relationship from ZTEK graph: Reciprocal relationship from BNR graph: iv) a decrease in amortized expenses … |
